A DVA N C E S I N SYNTHETIC AND B I O LO G I C A L CHEMISTRY Peter B. Dervan
The Welch Foundation hosts its 61st Annual Conference
Bren Professor of Chemistry
on Chemical Research | October 23-24, 2017, Houston, TX
California Institute of Technology The 2017 Welch Conference on Chemical Research is organized to
Speakers and Session Leaders From Molecules to Medicine Tadhg P. Begley, Texas A&M University Peter G. Schultz, The Scripps Research Institute
provide advances in chemistry with applications in biology, medicine and materials. A goal of synthetic chemistry is the discovery or invention of new properties. The late Nelson Leonard described this as “syntheses with a purpose.”
Samuel H. Gellman, University of Wisconsin-Madison
In a session on chemical biology, renowned scientists will describe small
David R. Liu, Harvard University
molecules that control stem cell self-renewal and differentiation, the
Brent Iverson, The University of Texas at Austin
use of alpha/beta peptide unnatural oligomers in biology, base editing
Jacqueline K. Barton, California Institute of Technology
technology that enables programmable correction of point mutations
K. C. Nicolaou, Rice University
in human genomes, redox chemistry at a distance mediated by DNA
Carolyn R. Bertozzi, Stanford University
through long range signaling and coordination of DNA repair, synthesis
Making Molecules and Materials Xiaowei Zhuang, Harvard University
of increasingly complex architectures for medicine, and new approaches to glycosylation-targeted cancer therapy.
Frances H. Arnold, California Institute of Technology
In a session on new materials, pathfinding researchers will spotlight the
Charles M. Lieber, Harvard University
evolution of enzymes that catalyze reactions not known in living systems,
Joseph M. DeSimone, University of North Carolina
invent nanoscale materials at the interface between the physical and
Stephan Link, Rice University
life sciences, reimagine 3D manufacturing based on continuous liquid
Catherine J. Murphy, University of Illinois at Urbana-Champaign
interface production technology, innovate selective chemistry on colloidal
Thomas E. Mallouk, The Pennsylvania State University
nanoscale objects, assemble nanosheets for catalytically active late-
Moungi Bawendi, Massachusetts Institute of Technology
transition metal nanoparticles, and apply quantum dots to bioimaging and energy harvesting. For registration information and a complete program, visit our website at www.welch1.org/conference/conference-overview
Join ACS in Washington, D.C.! Protecting Life’s Elements Meet the ACS Member Insurance Program Team
Plans for Every Element of Life
We can’t wait to see you in D.C.!
Discover Peace of Mind Sponsored by the Board of Trustees Group Insurance Plans for ACS Members Your Colleagues Working For You!
*Plans underwritten by New York Life Insurance Company, 51 Madison Avenue, New York, NY 10010, under Policy Form GMR. Brokered and administered by Pearl Insurance, 1200 E. Glen Ave., Peoria Heights, IL 61616.
California Insurance License #0F76076, AR# 1322
172079-B-ACS-AP-MAG-PAD
Business Concentrates FINANCE
Industrial demand boosts earnings Manufacturers’ need for chemicals drove increases in second quarter Chemical firms reporting second-quarter earnings say manufacturers are demanding more materials of all kinds than they did a year ago. The theme marks a shift from 2016, when consumer markets drove earnings growth. “Global economic activity is increasing, with notable strength in manufacturing, investment, and trade,” commented Dow Chemical CEO Andrew N. Liveris. Dow hiked prices 5% in the quarter and saw sales volumes rise 3% on strong demand for performance materials, plastics, and consumer chemicals. Performance products, including dispersants and pigments, helped drive sales and earnings higher at BASF. Growth in demand for polyurethane intermediates and a rebound in performance products powered Huntsman Corp.’s earnings, which rose almost 65%.
pany said strong demand and constrained supply of intermediates caused polyurethane and polycarbonate prices to rise. As a result, earnings more than doubled to At DuPont, volumes grew by 6% on fa$568 million compared with the prior-year vorable market conditions for electronic chemicals, performance materials, and ma- quarter. Covestro reported it is investing in additional plant caterials for safety and propacity in Shanghai and tection. In a conference other locations. call with investors, CEO “We want to continue Ed Breen said DuPont’s Broad demand for materials to take advantage of the industrial biosciences raises sales, earnings. ongoing robust demand business was buoyed for our products as much by increasing demand Sales Earnings as we can,” said Markus for Sorona polymers. In 2.0% 3.5% AkzoNobel Steilemann, Covestro’s addition, volumes rose chief commercial officer. 8% in the agriculture BASF 12.0 37.0 Similarly, Celanese segment, due in part to Celanese 11.8 4.5 saw demand grow in higher demand for crop Covestro 17.0 110.0 its acetyls and maprotection chemicals. Dow Chemical 15.7 24.0 terials businesses, Industrial buyers spurring it to raise heated up the second DuPont 5.1 6.0 earnings expectations quarter at Covestro, the Huntsman 5.3 63.5 for the year.—MELODY former materials business of Bayer. The comBOMGARDNER Sources: Companies
Second-quarter results
Tuesday, August 22, 2017 JW Marriott, Washington, D.C. 8pm Poster Session & Reception Capitol Ballroom
9pm Ceremony Grand Ballroom
10pm After Party Capitol Ballroom
www.acs.org/chemluminary
14
C&EN | CEN.ACS.ORG | JULY 31, 2017
MATERIALS
Corning invests in glass innovation
CR E DI T: CO R N I N G
Company to spend $4 billion on new material for pharmaceutical vials Corning plans to spend $4 billion to build facilities in the U.S. that manufacture a novel aluminosilicate glass for the packaging of injectable drugs. President Donald J. Trump announced the investment at a White House event promoting his initiative to increase manufacturing employment in the U.S. Also present were Corning CEO Wendell P. Weeks and the CEOs of the drug companies Merck & Co. and Pfizer. Corning said it will make an initial investment of $500 million to expand existing glass facilities in New York and New Jersey and build a new plant in the southeastern U.S. One thousand jobs will be created in the initial phase, the firm said, and 4,000 jobs by the time the investment program is done. Corning plans to work with the pharma-
Pharmaceutical vials made with Corning’s Valor glass.
ceutical packaging firms Gerresheimer and Stevanato to bring the new glass to the drug market. Such firms typically form containers out of borosilicate glass, which contains at least 5% boron oxide to help resist temperature change and corrosion. However, Robert Schaut, a glass scientist at Corning, explains that boron volatilizes when the glass is heated and molded into vials, leading to heterogeneity and microscopic surface delamination. In the new glass, called Valor, Corning replaced the boron with aluminum, reducing volatility and eliminating delamination, the firm says. A second Corning innovation was the use of ion exchange to replace some of the sodium ions in the glass with larger potassium ions, creating a compressive stress layer that increases glass strength.
The ion-exchange process is an optimized version of the one Corning uses to create its durable Gorilla glass for smartphone screens, Schaut says. At a demonstration at the White House event, Trump used a device to apply a more-than-450-kg load to a Valor vial without breaking it. Conventional vials, in contrast, break under about 20 kg of load. In a third innovation, Corning added a low-coefficient-of-friction surface to minimize vial-against-vial rubbing on filling lines. Generation of glass particles, which can contaminate drugs, is reduced by up to 96%, the company says. Merck says it plans to convert several injectable products to Valor, pending regulatory approvals. Pfizer says it is working with Corning to assess Valor at several of its manufacturing sites.—MICHAEL MCCOY
A Family of Custom Robotics
Precision Temperature Controllers
for Every Application and Every Budget You own the code!!
J-KEM releases the original source code with every robot. Making your robot your solution.
Eclipse Robotics
From $25,000
Customized deck size from 200 x 200mm to 1000 x 1000mm. High resolution: ±0.02mm
·
Fluid transfer
· Capping · Weighing · Mixing
· 0.1o C regulation of any volume from 10 Pl to 100 L. · < 1o C overshoot of the setpoint · Built for safety critical applications
SCARA Robotics From $80,000
Transfer solids Virtually unlimited operations with 4and 6-axis robotics
Endeavour Robotics From $12,000 The perfect instrument for fraction collectors, dilution, sorting, cherry picking, or sample preparation applications.
J-KEM Scientifc, Inc.
· Drug analysis · Extractions · Capping · Centrifugation (800) 827-4849
· Works with all heater types · ·
* Heating mantles * Ovens * Hot plates * Furnaces Safety Controllers with Primary and Back-up meters Free KEM-Net software for: Multi-temperature ramps Graphics & GMP compliant
[email protected] www.jkem.com JULY 31, 2017 | CEN.ACS.ORG | C&EN
15
Time flies
and so do advances in energy research
with ACS Energy Letters Celebrating the 1st anniversary of the journal’s inaugural issue with ENERGY EXPRESS — a new manuscript type that lets authors publish preliminary indings with great speed
READ THE JOURNAL AND SUBMIT YOUR RESEARCH AT
pubs.acs.org/acsenergylett
antivirals to prevent HIV infection in the first place. Most people who have HIV and are engaged in their care are well served by their regimens of one to two pills per day, says Paul Edward Sax, clinical director of the division of infectious diseases at Brigham & Women’s Hospital. But, Sax adds, many people living with HIV “wish for something that frees them from having to take pills every day. So there is patient interest, even among those doing well.” Sax consults with, or is on the scientific advisory board of, multiple pharmaceutical companies, including Gilead. In other words, by the time Gilead researchers arrived at a stable, potent compound, poor solubility was not necessarily an issue because it was a prime candidate to become an injected long-acting therapy. “Without a doubt, we were never thinking about a long-acting drug,” Tse acknowledges. At the February meeting, Gilead unveiled data in rats showing its tool compound GS-CA1 is active for as long as 10 weeks. Gilead researchers are now working to formulate a subcutaneous injection of its drug candidate that could be dosed once a month or even quarterly. UPenn’s Tebas cautions that a lot can
“I firmly believe that every single atom that’s on that molecule is important.” —Winston Tse, medicinal chemist, Gilead Sciences happen between data in cells or rats and trials in humans. Moreover, Gilead isn’t the only firm working on a long-acting drug. Last fall, ViiV Healthcare, an HIV-focused company that is majority owned by GlaxoSmithKline, launched a Phase III study of a once-monthly injectable treatment. The ViiV therapy combines a new integrase inhibitor, cabotegravir, with
an approved nonnucleoside reverse transcriptase inhibitor, rilpivirine. Last week, ViiV shared results from a midphase study showing the viral load was better controlled among people taking the long-acting treatment than for those taking oral antivirals. ViiV is also studying whether cabotegravir given once every two months could prevent new HIV infections. Cihlar acknowledges that ViiV’s two drugs have a significant lead. But both require an intramuscular injection, which could mean a monthly trip to the doctor, of a fairly sizable amount of drug, he notes. “We certainly want to go beyond that—less frequent and easier to administer,” he says. “Maybe the reasonable ambitious target would be once every three months.” Gilead is now determining the appropriate drug, if any, to pair with its lead molecule and expects to start a clinical trial next year. It will be the first time an HIV capsid inhibitor is tested in humans. Tse says he’ll be nervous, but gratified, when the first patient is dosed with his drug. After all, the most recent novel HIV treatment, an integrase inhibitor, was approved more than 10 years ago. “New mechanisms in HIV don’t happen very often,” he says. ◾
JULY 31, 2017 | CEN.ACS.ORG | C&EN
25
scaffolds might be used in a variety of biotechnology and medical applications, the team notes in its Science paper (2017, DOI: 10.1126/science.aan0693). To achieve the milestone, the researchers used computer protein design and high-throughput synthesis to produce 15,000 miniproteins, of which 2,500 folded stably (without the help of chaperones). Then they analyzed the characteristics of the stably folded proteins to quantify what success looked like. “If you just make random sequences, it’s rare that they would fold,” Baker says. The team found that stable proteins need to bury a surface area of 30 Å2 for each residue of buried hydrocarbon, a criterion that paves the way for tactical design of additional novel folds. Anfinsen would have surely been fascinated by the new work. Before his death in 1995, the biochemist exchanged letters with chaperone expert R. John Ellis at Warwick University, expressing his interest and excitement about the then-nascent chaperone field and his desire to include this new research in classes he taught to students. If he were still alive today, Anfinsen would marvel at the way the field has developed—the protein-folding pioneer might even be inspired to unfold the sails of his boat and go for a reflective glide. ◾
Power your Career in the ACS Booth in Washington DC The ACS Booth is your opportunity to experience the world’s largest scientiic society all on one carpet! • Experience SciFinder®, Chemistry Class AdvantageTM and all the latest research worklow solutions from CAS • Complete the peer-review quiz and bring your conirmation to ACS Publications for a special giveaway • Discuss how to achieve your career goals with ACS Career Navigator™ • Tell us how you advance, connect, share and discover at MyACS • Help us reveal the identity of C&EN’s “Talented 12” for 2017
Visit us in the ACS Booth! American Chemical Society
38
C&EN | CEN.ACS.ORG | JULY 31, 2017
EXHIBIT HOURS Sunday, August 20 • 6:00 pm – 8:30 pm Monday, August 21 • 9:00 am – 5:00 pm Tuesday, August 22 • 9:00 am – 5:00 pm
Whether looking for educational resources, powerful research tools, ACS Member Insurance, C&EN, future meeting dates and locations, mole dolls or other ACS merchandise, WE HAVE IT ALL FOR YOU.
©2017 American Chemical Society. B1701
®
CR E DI T: S CI E N CE/A AAS
included 100 protein synthetic biology. folds not found in the Although reProtein Data Bank searchers have long and 200 membrane understood why proproteins (Science 2017, teins are driven to DOI: 10.1126/science. fold—to bury hydroaah4043). To prove phobic side chains— their predictions were they have not been accurate, Baker and particularly successhis team initially deful at predicting how posited some of their a protein sequence forecasted structures will fold nor at deinto public databassigning entirely new es. In the months sequences that stably afterward, structural collapse into 3-D biologists serendipstructures, explains itously solved—and the University of Washington’s David Researchers have designed four new confirmed—the 3-D conformation of six of Baker. After decades synthetic protein folds never before these unknown protein of work in the area, evolved by nature. families. his group reported Then in July, the team reported that success on both fronts this year. it had designed protein sequences that In January, Baker and colleagues preadopted four protein topologies never dicted the 3-D conformations of 12% of the protein families that still had unknown before seen in nature. Although the proteins were small—shorter than 50 amino structure, thanks to a marriage of maacids long—the feat was a milestone for chine learning, big data from microbiome synthetic biology. Because many of the projects, Baker’s Rosetta protein folding designed proteins “are more stable than algorithm, and a distributed network of any comparably sized monomeric proteins volunteer computers. The 600 newly in the [Protein Data Base],” the sturdy determined protein family structures
SYMPOSIA RECOMMENDED BY THE ACS PRESIDENT Photo: Peter Cutts Photography
ACS Pharma Leaders: Working Together to Make a Diference (Sponsored by MPPG and Cosponsored by PRES)
Monday, August 21 • 1:00 PM – 4:00 PM Walter E. Washington Convention Center, Room 146C
Advancing Graduate Education: Opportunities & Challenges (Sponsored by CHED and Cosponsored by PRES) Allison A. Campbell, Ph.D. ACS President
Sunday, August 20 • 8:30 AM – 5:00 PM Grand Hyatt Washington, Independence Ballroom C
Biomass to Fuels & Chemicals: Research, Innovation & Commercialization (Sponsored by ENFL and Cosponsored by PRES, ENVR, MPPG, SCHB & WCC)
Tuesday, August 22 • 8:00 AM – 4:40 PM Walter E. Washington Convention Center, Room 141
Earle B. Barnes Award for Leadership in Chemical Research Management Symposium in Honor of Laurie Locascio: Why Not Me? Changing the Face of Leadership in Science
Journey to Mars: Materials, Energy & Life Sciences (Sponsored by POLY and Cosponsored by PRES & MPPG)
Tuesday, August 22 • 8:30 AM – 3:30 PM
(Sponsored by ANYL and Cosponsored by PRES)
Marriott Marquis Washington, DC, Shaw
Tuesday, August 22 • 2:00 PM – 4:30 PM Grand Hyatt Washington, Constitution Ballroom E
4:00 PM – 5:45 PM Marriott Marquis Washington, DC; Independence Salon D/E
GSSPC: Standing on the Shoulders of Giants: Developing Chemistries for Improved Global Health (Sponsored by CHED and Cosponsored by PRES, ANYL, BIOT, BMGT, CARB, CELL, COLL, GEAB, MEDI, and POLY; Virginia Tech Institute for Critical Technology and Applied Sciences, Department of Chemistry, College of Science, and the Department of Materials Science and Engineering; BASF; and Accounts of Chemical Research, ACS Biomaterials Science & Engineering, ACS Chemical Biology, ACS Infectious Diseases, ACS Macro Letters, ACS Synthetic Biology, Biochemistry, Bioconjugate Chemistry, Biomacromolecules, The Journal of Organic Chemistry, Journal of Medicinal Chemistry, Macromolecules, ACS Central Science, and Acta Biomaterialia)
Tuesday, August 22 • 9:00 AM – 4:15 PM Grand Hyatt Washington, Independence Ballroom D/E
Ladies in Waiting for Nobel Prizes: Overlooked Accomplishments of Women Chemists (Sponsored by HIST and Cosponsored by PRES & PROF)
Tuesday, August 22 • 8:25 AM – 4:45 PM Grand Hyatt Washington, Declaration A/B
Sustaining Water Resources: Environmental and Economic Impact (Sponsored by MPPG and Cosponsored by PRES, ENVR, GEOC & I&EC)
Monday, August 21 • 8:30 AM – 12:20 PM Walter E. Washington Convention Center, Room 203 A/B
Transformative Research & Excellence in Education [TREE] Award Symposium (Sponsored by COMSCI and Cosponsored by PRES, BIOL, COLL, COMP, ENFL, INOR & PHYS)
Monday, August 21 • 1:30 PM – 5:25 PM Walter E. Washington Convention Center, Room 155
®
American Chemical Society
EMPOWER SCIENTISTS OF THE FUTURE
Capture the imagination of curious children with fun
science activity books! Shop now at acs.org/sciencebooks. JUNE 26, 2017 | CEN.ACS.ORG | C&EN
43
Photo: Peter Cutts Photography
Allison A. Campbell, Ph.D. ACS President
PRESIDENTIAL SYMPOSIA AND EVENTS
SATURDAY, AUGUST 19, 2017
TUESDAY, AUGUST 22, 2017
12:00 PM - 4:00 PM
8:30 AM - 5:00 PM
Presidential Outreach Event: Exploring Our World Through Chemistry
Understanding the Chemistry of Our Planet
Cosponsored by CCA American Chemical Society 1155 16th Street, NW Washington, DC 20036
SUNDAY, AUGUST 20, 2017 1:00 PM - 4:30 PM
Walter E. Washington Convention Center, Room 145A
(Sponsored by the National Science Foundation and Cosponsored PRES)
8:00 AM - 12:00 PM The World of Funding Opportunities in Chemistry
(Cosponsored by BIOL, CARB, CEI, CELL, CEPA, CINF, COLL, CPRC, CTA, DAC, I&EC, INOR, ORGN, PROF, SCHB & YCC)
ACS Town Hall: National Academies’ Frontiers of Materials Research Decadal Survey
The Road Less Traveled: Career Opportunities in the Government Sector (Sponsored by YCC and Cosponsored by PRES and PROF)
(Sponsored by the National Science Foundation and Cosponsored by PRES)
Walter E. Washington Convention Center, Ballroom C
(Sponsored by the National Science Foundation and Cosponsored by PRES and ACS President-Elect Peter K. Dorhout)
2:00 PM - 5:00 PM
Federal Funders Town Hall Meeting
(Cosponsored by BIOL, BMGT, CARB, CEI, CELL, CEPA, CINF, COLL, CPRC, DAC, GEOC, I&EC, INOR, ORGN, SCHB & YCC, the Chemical Sciences Roundtable [CSR], and the Society for Science at User Research Facilities [SSURF])
Science Communications: The Art of Developing a Clear Message: A Joint Symposium with the Royal Society of Chemistry Marriott Marquis Washington, DC; Liberty Salon M
1:00 PM - 2:30 PM
3:00 PM - 5:00 PM Speed Coaching with Federal Funders Walter E. Washington Convention Center, Ballroom C
5:30 PM - 7:30 PM LGBTQ+ Presidential Reception
Walter E. Washington Convention Center, Ballroom C
(Cosponsored by ACS President-Elect Peter K. Dorhout, BIOL, BMGT, CARB, CEI, CELL, CEPA, CINF, CMA, COLL, CPRC, CTA, DAC, GEOC, INOR, NOGLSTP, ORGN, PA&PR, PROF, SCC & YCC)
11:30 AM - 3:00 PM
W Hotel, Altitude Room (Roof Level)
(Sponsored by The National Academies of Sciences, Engineering, and Medicine and Cosponsored by PRES and ACS President-Elect Peter K. Dorhout)
A very special thank you to our inancial sponsors ACS PresidentElect Peter K. Dorhout, CARB, CEI, CEPA, CONC, PA&PR, BIOL, CMA, CPRC & SCC
Marriott Marquis Washington, DC; George Washington University Room
Marriott Marquis Washington, DC; Union Station
OTHER SYMPOSIA RECOMMENDED BY THE ACS PRESIDENT
Presidential Workshop: ACS Chemistry on the Hill Advocacy Workshop [INVITATION ONLY]
ACS Pharma Leaders: Working Together to Make a Diference
Walter E. Washington Convention Center, Room 147B
Walter E. Washington Convention Center, Room 146C
MONDAY, AUGUST 21, 2017
Advancing Graduate Education: Opportunities & Challenges
8:30 AM - 4:00 PM
(Sponsored by CHED and Cosponsored by PRES)
Chemistry in an Evolving Political Climate: Research Priorities and Career Pathways in Public Policy (Sponsored by YCC and Cosponsored by PRES, BIOL, CARB, CCPA, CEI, CELL, CEPA, CHED, CINF, COLL, COMSCI, CPRC, DAC, GEOC, IAC, I&EC & SCHB)
Marriott Marquis Washington, DC; Chinatown
8:30 AM - 4:30 PM Building a Safety Culture Across the Chemistry Enterprise
(Sponsored by MPPG and Cosponsored by PRES)
Grand Hyatt Washington, Independence Ballroom C
Biomass to Fuels & Chemicals: Research, Innovation & Commercialization (Sponsored by ENFL and Cosponsored by PRES, ENVR, MPPG, SCHB & WCC)
Walter E. Washington Convention Center, Room 141
GSSPC: Standing on the Shoulders of Giants: Developing Chemistries for Improved Global Health
(Sponsored by SCHB and Cosponsored by PRES, BIOL, CARB, CCPA, CEI, CELL, CEPA, CINF, COLL, CPRC, DAC, ETHX & YCC)
(Sponsored by CHED and Cosponsored by PRES, ANYL, BIOT, BMGT, CARB, CELL, COLL, GEAB, MEDI, and POLY; Virginia Tech Institute for Critical Technology and Applied Sciences, Department of Chemistry, College of Science, and the Department of Materials Science and Engineering; BASF; and Accounts of Chemical Research, ACS Biomaterials Science & Engineering, ACS Chemical Biology, ACS Infectious Diseases, ACS Macro Letters, ACS Synthetic Biology, Biochemistry, Bioconjugate Chemistry, Biomacromolecules, The Journal of Organic Chemistry, Journal of Medicinal Chemistry, Macromolecules, ACS Central Science, and Acta Biomaterialia)
Marriott Marquis Washington, DC; Magnolia
Grand Hyatt Washington, Independence Ballroom D/E
(Cosponsored by BIOL, BMGT, CARB, CCS, CEI, CELL, CEPA, CHAS, CINF, COLL, CPRC, CTA, DAC, ETHX, I&EC, INOR, ORGN, PROF, SCHB & YCC)
Marriott Marquis Washington, DC; Marquis Salon 1/2
1:00 PM - 5:00 PM Working in the Public Sector: Running for Elected Oice
Earle B. Barnes Award for Leadership in Chemical Research Management Symposium in Honor of Laurie Locascio: Why Not Me? Changing the Face of Leadership in Science (Sponsored by ANYL and Cosponsored by PRES)
Grand Hyatt Washington, Constitution Ballroom E
Journey to Mars: Materials, Energy & Life Sciences (Sponsored by POLY and Cosponsored by PRES & MPPG)
Marriott Marquis Washington, DC; Shaw and Independence Salon D/E
Ladies in Waiting for Nobel Prizes: Overlooked Accomplishments of Women Chemists (Sponsored by HIST and Cosponsored by PRES & PROF)
Grand Hyatt Washington, Declaration A/B
Sustaining Water Resources: Environmental and Economic Impact (Sponsored by MPPG and Cosponsored by PRES, ENVR, GEOC, I&EC)
Walter E. Washington Convention Center, Room 203A/B
Transformative Research & Excellence in Education [TREE] Award Symposium (Sponsored by COMSCI and Cosponsored by PRES, BIOL, COLL, COMP, ENFL, INOR & PHYS)
Walter E. Washington Convention Center, Room 155
www.acs.org/DC2017
JOIN US FOR THE
ACS BOARD OF DIRECTORS REGULAR SESSION
Sunday, August 20, 2017 Noon - 1:00 p.m. Walter E. Washington Convention Center – Ballroom Doors open at 11:45 a.m.
Sandwiches and soft drinks while supplies last
American Chemical Society
symposium.acs.org/2017/Shanghai
Don’t miss the opportunity to join the world’s leading researchers for three days of innovation in molecular synthesis. Attend lectures by world-renowned scientists, poster sessions, short talks selected from outstanding abstracts, exclusive “Meet the Speakers and Editors” events, and more.
REGISTER NOW!
EARLY REGISTRATION ENDS AUGUST 21 Register early to qualify for a discounted registration fee, to receive membership to the American Chemical Society, and to get one FREE student ticket!
WE LIVE EFFICIENCY
NEW PURIFICATION TEAM Introducing the new Agilent InfinityLab LC Purification Solutions! A complete and scalable portfolio based on a single platform gives you the choice to tailor a system to meet your lab’s current and future needs. Team up with Agilent and get on top of your analytical and preparative-scale LC purification challenges. Live efficiency. Live purification. www.agilent.com/chem/livepreplc #WeLiveEfficiency #EfficientUHPLC
© Agilent Technologies, Inc. 2017
